KRAS and cancer: In vitro studies have also shown that divarasib is 5 to 20 times as potent and up to 50 times as selective compared to the KRAS G12C inhibitors sotorasib and adagrasib (Purkey, H. Discovery of GDC-6036, a clinical stage treatment for KRAS G12C-positive cancers.